5/7 Psychiatric Genomics Consortium: Advancing Discovery and Impact

5/7 精神病学基因组学联盟：推进发现和影响

• 批准号: 10577804
• 负责人: Cathryn Lewis
• 金额: $ 49.94万
• 依托单位: CARDIFF UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-04-06 至 2026-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10577804
• 关键词: Acceleration; Address; Affect; Alleles; Biological; Biology; Biotechnology; Cells; Clinical; Collaborations; Communication; Communities; Country; DNA Resequencing; Data; Diagnostic; Disease; Educational Materials; Ensure; Epidemiology; Facebook; Family; Fostering; Funding; Genes; Genetic; Genetic Variation; Genets; Genome; Genomics; Goals; Individual; Industry; Institution; Investments; Journals; Knowledge; Learning; Life; Maps; Measures; Medical; Medicine; Mendelian randomization; Mental disorders; Meta-Analysis; Methods; Mission; Modeling; Molecular; National Institute of Mental Health; Nature; Neurosciences; Outcome; Paper; Patients; Phase; Phenotype; Productivity; Psychiatric Diagnosis; Psychiatry; Recording of previous events; Reproducibility; Research Personnel; Resistance; Resources; Risk; Risk Factors; Science; Scientist; Source; Symptoms; Therapeutic; Time; Twitter; Update; Variant; Work; base; biobank; career; case control; digital media; education resources; exome; exome sequencing; experimental study; functional genomics; genetic architecture; genetic pedigree; genome sequencing; genome wide association study; genomic data; genomic locus; improved; innovation; insight; instrument; novel; novel therapeutics; outreach; patient stratification; patient subsets; predict clinical outcome; psychiatric genomics; rare variant; severe psychiatric disorder; statistics; success; therapeutic development; translational potential; whole genome; working group

Project Summary Now in its 13th year, the Psychiatric Genomics Consortium is perhaps the most innovative and productive experiment in the history of psychiatry. The PGC unified the field and attracted a cadre of outstanding scientists (802 investigators from 157 institutions in 41 countries). PGC work has led to identification of ~500 genetic loci in the 11 psychiatric disorders we study. Our work has led to 320 papers, many in high-profile journals (Nature 3, Cell 5, Science 2, Nat Genet 27, Nat Neurosci 9, Mol Psych 37, Biol Psych 25). As summary statistics are freely available, psychiatric disorders often feature prominently in papers by non-PGC investigators. To advance discovery and impact, we propose to continue the work of the PGC across 11 disorder groups. Considerable new data are coming in the next five years. We thus can rapidly and efficiently increase our knowledge of the fundamental basis of major psychiatric disorders. Aim 1: we will continue to advance genetic discovery for severe psychiatric disorders in all working groups, systematically interface with large biobank studies to ensure maximal comparability, and aggressively promote new studies of individuals with psychiatric disorders from diverse ancestries to increase discovery and improve fine-mapping. Aim 2: most studies analyze common variation (Aim 1), rare CNV (Aim 2), and rare exome/genome resequencing results (via collaboration) in isolation: we will apply an integrative framework to rigorously evaluate the contributions of all measured types of genetic variation on risk for psychiatric disorders. Aim 3: we will move beyond classical case-control definitions to a more biologically-based and nuanced understanding by enabling large trans-diagnostic studies, convene trans-disciplinary teams to use genetics to address unresolved questions about the nature of psychiatric disorders, and to promote large studies of the severest cases seen in psychiatric practice (leveraging the global reach of PGC investigators). Aim 4: we will work to maximize the impact of our work via translational efforts: close collaborations with neuroscience consortia to understand the biological implications of our findings; work to identify modifiable causal risk factors; and work to robustly predict clinical outcomes and identify patient subsets. Aim 5: we will increase impact of our work by extending and formalizing outreach to different communities (including pharma and biotech), via digital media (Twitter, Facebook, Wikipedia), and by developing, distributing, and updating resources/educational material for patients, families, and medical professionals. We will convene a Scientific Advisory Board to ensure we respond positively to those invested in our results Successful completion of this body of work will greatly advance knowledge of the genetic basis of psychiatric disorders with potentially major nosological and treatment implications. These goals are consistent with a core mission of the NIMH, and the central idea of the PGC: to convert the family history risk factor into biologically, clinically, and therapeutically meaningful insights.

项目总结